<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Brucellosis: Treatment and prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Brucellosis: Treatment and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Brucellosis: Treatment and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mile Bosilkovski, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3202188985"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Brucellosis (also known as "undulant fever," "Mediterranean fever," or "Malta fever") is a zoonotic infection transmitted to humans from infected animals (cattle, sheep, goats, camels, pigs, or other animals) by ingestion of food products (such as unpasteurized dairy products) or by contact with tissue or fluids. It is the most common zoonosis worldwide and is an important public health problem in many resource-limited countries [<a href="#rid1">1-4</a>].</p><p>The treatment and prevention of brucellosis will be reviewed here. The epidemiology, microbiology, clinical manifestations, and diagnosis of brucellosis are discussed separately. (See  <a class="medical medical_review" href="/d/html/3140.html" rel="external">"Brucellosis: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2047787653"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H1401104117"><span class="h2">General approach</span><span class="headingEndMark"> — </span>The goal of brucellosis therapy is to control the illness and prevent complications, relapses, sequelae, and mortality [<a href="#rid5">5-7</a>]. (See <a class="local">'Outcome'</a> below.)</p><p>General principles of brucellosis treatment include use of antibiotics with activity in acidic intracellular environments (such as <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> and <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>), use of combination therapy (given high relapse rates with monotherapy), and prolonged duration of treatment [<a href="#rid8">8-10</a>].</p><p>Issues related to treatment of brucellosis in the absence of focal disease due to spondylitis, neurobrucellosis, or endocarditis are discussed in the section below. These regimens are used for treatment of osteoarticular disease in the absence of spondylitis (such as sacroiliitis, peripheral arthritis), as well as for treatment of other forms of focal disease (such as genitourinary involvement, pulmonary involvement, etc). (See  <a class="medical medical_review" href="/d/html/3140.html" rel="external">"Brucellosis: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Complications'</a>.)</p><p class="headingAnchor" id="H885909068"><span class="h3">Nonpregnant adults</span></p><p class="headingAnchor" id="H816996710"><span class="h4">Clinical approach</span><span class="headingEndMark"> — </span>Regimens for the treatment of adults with brucellosis (in the absence of focal disease due to spondylitis, neurobrucellosis, or endocarditis) include  (<a class="graphic graphic_table graphicRef122172" href="/d/graphic/122172.html" rel="external">table 1</a>) [<a href="#rid2">2,11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> (oral) for 6 weeks PLUS <a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a> (parenteral) for the first 14 to 21 days </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> (oral) for 6 weeks PLUS <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> (parenteral) for the first 7 to 10 days</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> (oral) PLUS <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> (oral), both for 6 weeks</p><p></p><p>The preferred regimen is <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> combined with an aminoglycoside; data from three meta-analyses demonstrate that this regimen is somewhat more effective than doxycycline-rifampin [<a href="#rid2">2,6,12-15</a>]. In a 2012 meta-analysis including nine studies and 930 patients with brucellosis treated with doxycycline-rifampin or doxycycline-streptomycin, doxycycline-rifampin was associated with a higher combined rate of treatment failure and relapse (18.2 versus 6.7 percent; odds ratio [OR] 3.17, 95% CI 2.05-4.91)<em> </em>[<a href="#rid12">12</a>]. Comparable outcomes have been observed with doxycycline-streptomycin and doxycycline-gentamicin [<a href="#rid12">12,16</a>]; in the above meta-analysis, no significant difference between these regimens was observed (OR 1.89, 95% CI 0.81-4.39) [<a href="#rid12">12</a>]. Treatment differences for other outcomes (such as complications or long term morbidity) have not been observed.</p><p>However, many favor doxycycline-rifampin since it is more convenient than parenteral therapy, may be better tolerated than aminoglycosides (which are associated with nephrotoxicity and ototoxicity) and is less costly [<a href="#rid2">2,9</a>]. Further study of oral regimens for treatment of brucellosis is needed. </p><p>Monotherapy regimens and regimens shorter than six weeks are not accepted treatment strategies for brucellosis, given high relapse rates with these approaches [<a href="#rid2">2,9,10</a>]. </p><p>Some studies have suggested a benefit associated with triple-drug therapy might improve the illness outcome without increasing the incidence of drug side effects [<a href="#rid17">17-22</a>]. This is not regarded as a routine approach [<a href="#rid2">2,10,12</a>] but may be considered on an individual basis [<a href="#rid2">2,23</a>].</p><p class="headingAnchor" id="H2244983436"><span class="h4">Alternative agents</span><span class="headingEndMark"> — </span>Alternative agents include fluoroquinolones and TMP-SMX, used in combination regimens:</p><p class="bulletIndent1"><span class="glyph">●</span>Fluoroquinolones may be used as alternative second or third agents in combination regimens containing <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> or <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> [<a href="#rid24">24-26</a>]. They are not appropriate first-line agents (given decreased activity in acidic environments, as well as cost), but may be beneficial in the setting of drug resistance, antimicrobial toxicity, and some cases of relapse [<a href="#rid24">24</a>]. Options include <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> (500 mg orally twice daily for six weeks) or <a class="drug drug_general" data-topicid="9715" href="/d/drug information/9715.html" rel="external">ofloxacin</a> (200 to 400 mg orally twice daily for six weeks). In a randomized trial including 61 patients with brucellosis treated with doxycycline-rifampin or ofloxacin-rifampin for 6 weeks, relapse rates were similar between the groups (3.2 versus 3.3 percent) and there was one case of treatment failure in the ofloxacin-rifampin group [<a href="#rid25">25</a>]. In a subsequent study including 118 patients with brucellosis treated with ofloxacin-rifampin, doxycycline-rifampin, or doxycycline-streptomycin, relapse rates were similar (12.8, 14.3, and 9.7 percent, respectively) [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TMP-SMX may be used as an alternative second or third agent in combination regimens containing <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> or <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> for treatment of patients with relapse or refractory disease [<a href="#rid2">2</a>]. Dosing consists of one double-strength tablet (160 mg TMP and 800 mg SMX) orally twice daily for six weeks. Based on limited data, the efficacy of doxycycline-TMP-SMX is similar to that of doxycycline-rifampin [<a href="#rid14">14</a>]; however, comparative randomized studies are limited. In addition, TMP-SMX should be used with caution for prolonged treatment of brucellosis given its broad spectrum of activity and potential for development of antimicrobial resistance.  </p><p></p><p class="headingAnchor" id="H2877028254"><span class="h3">Children</span><span class="headingEndMark"> — </span>Regimens for treatment of children ≥8 years with brucellosis (in the absence of spondylitis, neurobrucellosis, or endocarditis) include  (<a class="graphic graphic_table graphicRef122172" href="/d/graphic/122172.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> (oral) PLUS <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> (oral), both for 6 weeks</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> (oral) for 6 weeks PLUS <a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a> (parenteral) for the first 14 to 21 days </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> (oral) for 6 weeks PLUS <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> (parenteral) for the first 7 to 10 days </p><p></p><p>Many favor doxycycline-rifampin for treatment of children ≥8 years with brucellosis since it is more convenient than parenteral therapy. (See <a class="local">'Nonpregnant adults'</a> above.)</p><p>Treatment of children &lt;8 years with uncomplicated brucellosis consists of <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) PLUS <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, both for 6 weeks  (<a class="graphic graphic_table graphicRef122172" href="/d/graphic/122172.html" rel="external">table 1</a>) [<a href="#rid1">1,2</a>]. Other acceptable regimens include either TMP-SMX or rifampin, in combination with an aminoglycoside [<a href="#rid28">28,29</a>]. <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> is not recommended for children &lt;8 years of age given risk for dental staining with prolonged duration of therapy.</p><p>The approach to treatment of uncomplicated brucellosis in children is based on studies in adults, observational data, and a randomized trial; cure rates are similar to those seen in adults [<a href="#rid18">18,28,30-37</a>]. (See <a class="local">'Nonpregnant adults'</a> above.)</p><p class="headingAnchor" id="H3902227185"><span class="h3">Pregnant women</span><span class="headingEndMark"> — </span>The optimal approach to management of pregnant women with brucellosis (in the absence of focal disease due to spondylitis, neurobrucellosis, or endocarditis) is uncertain. Tetracyclines are contraindicated in pregnancy; data regarding the efficacy of alternative agents are limited to observational studies [<a href="#rid10">10,38-40</a>]. </p><p>For pregnant women &lt;36 weeks gestation, we treat with <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> plus TMP-SMX (with folate supplementation), both for six weeks  (<a class="graphic graphic_table graphicRef122172" href="/d/graphic/122172.html" rel="external">table 1</a>) [<a href="#rid41">41</a>]. Some studies have suggested an association between use of TMP/SMX during the first trimester of pregnancy and increased risk of neural tube defects (due to interference with folate metabolism) [<a href="#rid42">42</a>]; however, one meta-analysis failed to identify significant adverse effects associated with the use of TMP/SMX during pregnancy [<a href="#rid43">43</a>].</p><p>For pregnant women ≥36 weeks gestation, we administer <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> monotherapy until delivery, given risk of neonatal kernicterus with the use of TMP-SMX in the last month of pregnancy. </p><p>After delivery, we continue combination therapy as in nonpregnant adults and advise that breastfeeding be postponed until after completion of treatment [<a href="#rid41">41</a>]. The total duration of treatment is six weeks. (See  <a class="medical medical_review" href="/d/html/493.html" rel="external">"Trimethoprim-sulfamethoxazole: An overview", section on 'Pregnancy and breastfeeding'</a> and <a class="local">'Nonpregnant adults'</a> above.)</p><p>Other regimens described in the literature as effective for treatment of brucellosis in pregnancy include <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> or TMP-SMX monotherapy or combination therapy with rifampin and an aminoglycoside, combination therapy with rifampin and <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, and combination therapy with rifampin and TMP-SMX and ceftriaxone [<a href="#rid10">10,38-41,44</a>]. </p><p>In the setting of postpartum relapse, a standard treatment regimen may be used [<a href="#rid2">2</a>]. (See <a class="local">'Nonpregnant adults'</a> above.)</p><p>In one study including 92 pregnant women with brucellosis, antepartum antimicrobial therapy with TMP-SMX or TMP-SMX-rifampin was protective against spontaneous abortion (relative risk 0.14, 95% CI 0.06-0.37) [<a href="#rid39">39</a>]</p><p class="headingAnchor" id="H1025604540"><span class="h3">Kidney or liver failure</span><span class="headingEndMark"> — </span>In patients with hepatic failure, we treat with an aminoglycoside in combination with either <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> or a fluoroquinolone. In patients with kidney failure, we treat with doxycycline plus <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> [<a href="#rid23">23</a>]. </p><p class="headingAnchor" id="H3382582278"><span class="h2">Treatment of specific complications</span></p><p class="headingAnchor" id="H810372958"><span class="h3">Spondylitis</span><span class="headingEndMark"> — </span>Issues related to treatment of <em>Brucella </em>spondylitis<em> </em>are discussed here; the approach to treatment of osteoarticular disease (such as peripheral arthritis and sacroiliitis) in the absence of spondylitis is described above. (See <a class="local">'General approach'</a> above.)</p><p>The optimal approach to treatment of <em>Brucella </em>spondylitis<em> </em>is uncertain; data are limited to observational studies [<a href="#rid9">9,45-50</a>]. A number of combination regimens have been used [<a href="#rid49">49</a>]. </p><p>For adults and children ≥8 years with spondylitis, we favor treatment with <a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a> (for the first 14 to 21 days) or <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> (for the first 7 to 14 days) PLUS <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (for at least 12 weeks) PLUS <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> (for at least 12 weeks)  (<a class="graphic graphic_table graphicRef122173" href="/d/graphic/122173.html" rel="external">table 2</a>) [<a href="#rid45">45-48,51</a>]. For children &lt;8 years, we substitute TMP-SMX for doxycycline. </p><p>For pregnant women with spondylitis, we favor treatment with <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> for 4 to 6 weeks PLUS <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> and TMP-SMX for 12 weeks  (<a class="graphic graphic_table graphicRef122173" href="/d/graphic/122173.html" rel="external">table 2</a>). For pregnant women ≥36 weeks gestation, we administer ceftriaxone and rifampin until delivery, given risk of neonatal kernicterus with the use of TMP-SMX in the last month of pregnancy. After delivery, we continue combination therapy as in nonpregnant adults; the total duration of treatment is at least 12 weeks. (See <a class="local">'Pregnant women'</a> above.)</p><p>Other regimens described in the literature for treatment of spondylitis include doxycycline-rifampin, doxycycline-streptomycin, ciprofloxacin-rifampin, doxycycline-rifampin-cotrimoxazole, and doxycycline-rifampin-ciprofloxacin [<a href="#rid45">45,47,49,52</a>].</p><p>The duration of therapy may be at least as important as the choice of antimicrobial agents; treatment for <em>Brucella</em> spondylitis for adults should consist of antibiotic therapy for at least 12 weeks [<a href="#rid48">48</a>]. In a meta-analysis including 32 observational studies and 303 patients, the failure rate was lower for patients treated ≥12 weeks than for patients treated ≤6 weeks (17 versus 43 percent) [<a href="#rid48">48</a>]. </p><p>For patients with persistent symptoms and/or radiographic findings, the duration of treatment should be extended beyond 12 weeks, based on individual patient circumstances. </p><p>The above approach is supported by an observational study including 18 patients with <em>Brucella </em>spondylitis treated with a combination of at least three antibiotics (doxycycline-rifampin plus <a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a> or TMP-SMX or <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>) for a median duration of therapy of 48 weeks (range 24 to 72 weeks); no relapses were observed (median follow-up 36.5 months) [<a href="#rid50">50</a>].</p><p>Surgery may be warranted in the setting of spinal instability, persistence or progression of neurologic deficit, vertebral collapse, or localized abscess (epidural or paravertebral) [<a href="#rid8">8,53</a>]. </p><p class="headingAnchor" id="H914370171"><span class="h3">Neurobrucellosis</span><span class="headingEndMark"> — </span>The optimal approach to treatment of neurobrucellosis is uncertain; data are limited to retrospective and observational studies [<a href="#rid54">54-57</a>].</p><p>For adults and children ≥8 with neurobrucellosis, we favor treatment with <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> for the first 4 to 6 weeks, PLUS <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> and <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, both for at least 12 weeks; the duration of therapy is often extended to 4 to 6 months  (<a class="graphic graphic_table graphicRef122174" href="/d/graphic/122174.html" rel="external">table 3</a>) [<a href="#rid54">54-57</a>]. For children &lt;8 years, we substitute TMP-SMX for doxycycline [<a href="#rid58">58-60</a>]. An alternative regimen consists of doxycycline-rifampin-TMP-SMX, all administered for at least 12 weeks [<a href="#rid56">56,57</a>]. </p><p>For pregnant women with neurobrucellosis, we favor treatment with <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> for the first 4 to 6 weeks, PLUS <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> and TMP-SMX both for at least 12 weeks  (<a class="graphic graphic_table graphicRef122174" href="/d/graphic/122174.html" rel="external">table 3</a>). For pregnant women ≥36 weeks gestation, we administer ceftriaxone and rifampin until delivery, given the risk of neonatal kernicterus with the use of TMP-SMX in the last month of pregnancy. After delivery, we continue combination therapy as in nonpregnant adults; the total duration of treatment is at least 12 weeks. (See <a class="local">'Pregnant women'</a> above.)</p><p>The total duration of treatment is at least three months and may be up to six months or longer. The duration of therapy should be tailored to individual patient circumstances including clinical assessment, cerebrospinal fluid findings, and follow-up radiographic imaging [<a href="#rid55">55,56,61</a>]. </p><p>The above approach is supported by a retrospective study including 215 patients with neurobrucellosis treated with <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, and either <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> or TMP-SMX; patients treated with ceftriaxone-based therapy had a lower rate of the combined outcome of relapse and treatment failure (3.6 versus 14.3 percent) [<a href="#rid57">57</a>]. </p><p>There is no role for routine use of corticosteroids for treatment of neurobrucellosis [<a href="#rid62">62</a>]. Use of steroids may be appropriate in the setting of neurobrucellosis complicated by iritis, papilledema, myelopathy, polyneuropathy, radiculopathy, encephalitis, and/or cranial nerve palsies [<a href="#rid23">23,63</a>].</p><p class="headingAnchor" id="H3254609299"><span class="h3">Endocarditis</span><span class="headingEndMark"> — </span>The optimal approach to treatment of <em>Brucella</em> endocarditis is uncertain; data are limited to small case series. In general, most patients with <em>Brucella</em> endocarditis require a combination of antimicrobial therapy and surgery for the best chance of cure [<a href="#rid3">3,64,65</a>]. Surgical consultation is warranted for all patients with <em>Brucella</em> endocarditis. </p><p>In one retrospective study including 308 cases of brucellar endocarditis, combined surgical plus medical treatment (compared with medical treatment only) was associated with reduced mortality (33 versus 7 percent) [<a href="#rid66">66</a>]. A small number of cases treated successfully with antimicrobial therapy alone have been reported; in some circumstances, this may be an acceptable approach in the absence of heart failure, large vegetations, valvular destruction, abscess, or a prosthetic valve [<a href="#rid23">23,67,68</a>]. </p><p>For adults and children ≥8 years with <em>Brucella</em> endocarditis, we favor treatment with a triple-combination antibiotic regimen including an aminoglycoside (<a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a> or <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>) for the first month, PLUS <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> and <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> both for at least 12 weeks  (<a class="graphic graphic_table graphicRef122175" href="/d/graphic/122175.html" rel="external">table 4</a>). An alternative approach consists of substituting a third-generation cephalosporin for the aminoglycoside [<a href="#rid64">64</a>]. For children &lt;8 years, we substitute TMP-SMX for doxycycline. </p><p>For pregnant women with <em>Brucella </em>endocarditis, we favor treatment with <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> for the first four to six weeks, PLUS <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> and TMP-SMX, both for at least 12 weeks  (<a class="graphic graphic_table graphicRef122175" href="/d/graphic/122175.html" rel="external">table 4</a>). For pregnant women ≥36 weeks gestation, we administer ceftriaxone and rifampin until delivery, given the risk of neonatal kernicterus with the use of TMP-SMX in the last month of pregnancy. After delivery, we continue combination therapy as in nonpregnant adults; the total duration of treatment is at least 12 weeks. (See <a class="local">'Pregnant women'</a> above.)</p><p>The minimum duration of therapy is 12 weeks; the duration of therapy is often extended for four to six months. The duration of therapy should be tailored to individual patient circumstances including clinical assessment and follow-up echocardiography. For patients with a prosthetic valve or abscess who do not undergo surgery, a prolonged duration of therapy is warranted. </p><p>In one study including 53 adults with <em>Brucella</em> endocarditis treated with ceftriaxone-streptomycin-rifampin, <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> (or <a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a>)-doxycycline-rifampin, ceftriaxone-doxycycline-rifampin, or oral agents only, mortality rates were 0, 5, 15, and 25 percent, respectively; however, the sample size was too small for statistical analysis [<a href="#rid69">69</a>]. </p><p>General issues related to management of endocarditis are discussed separately. (See  <a class="medical medical_review" href="/d/html/118215.html" rel="external">"Overview of management of infective endocarditis in adults"</a>.)</p><p class="headingAnchor" id="H257109836"><span class="h2">Relapse</span><span class="headingEndMark"> — </span>Relapse usually occurs within the first six months following completion of treatment, but may occur up to 12 months later [<a href="#rid8">8,70-72</a>]. Relapse of symptoms should prompt assessment for focal disease. Relapse due to antibiotic resistance is rare; nonetheless, antimicrobial susceptibility should be performed on all culture isolates. (See  <a class="medical medical_review" href="/d/html/3140.html" rel="external">"Brucellosis: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Relapse'</a>.)</p><p>Most relapses can be treated successfully with a repeat course of a standard regimen [<a href="#rid2">2,4,8,70,73</a>]. Patients with second or third relapse should be treated with an alternative regimen. (See <a class="local">'Alternative agents'</a> above.)</p><p class="headingAnchor" id="H3756538537"><span class="h2">Disease due to vaccine strain RB51</span><span class="headingEndMark"> — </span><em>Brucella</em> RB51 is a live attenuated cattle vaccine strain which can be shed in milk and can cause infection in humans who drink the milk without pasteurization; the strain is resistant to <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> [<a href="#rid74">74</a>].</p><p>Uncomplicated brucellosis associated with exposure to <em>Brucella</em> RB51 may be treated as follows [<a href="#rid74">74</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Adults and children ≥8 years: <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> and TMP-SMX for 6 weeks</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children &lt;8 years: TMP-SMX for 6 weeks PLUS <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> for 7 to 10 days</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnant women: TMP-SMX (monotherapy for 6 weeks), or TMP-SMX in combination with <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> (7 to 10 days) or <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> (4 to 6 weeks)</p><p></p><p>The dosing is as summarized above. (See <a class="local">'General approach'</a> above.)</p><p class="headingAnchor" id="H935027286"><span class="h1">LIMITED ROLE OF FOLLOW-UP SEROLOGY</span><span class="headingEndMark"> — </span>In general, routine follow-up serologic testing is not useful for guiding duration of therapy; it is not always possible to distinguish serologically between persistent (active) and past (inactive) infection [<a href="#rid75">75-77</a>]. </p><p>Given lack of reliable laboratory criteria for definitive cure [<a href="#rid78">78</a>],<em> </em>periodic clinical assessment in combination with serologic follow-up is advisable; and the interpretation of serologic tests should be correlated with clinical history including presenting clinical manifestations and treatment history [<a href="#rid79">79-81</a>]. In such cases, the most useful laboratory tools include the Coombs test, the immunocapture agglutination (Brucellacapt) test, enzyme-linked immunosorbent assay (ELISA) immunoglobulin (Ig)G, and the 2-mercaptoethanol (2-ME) agglutination test [<a href="#rid81">81-83</a>]. (See  <a class="medical medical_review" href="/d/html/3140.html" rel="external">"Brucellosis: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Serologic tests'</a>.) </p><p>Decline in IgG titer has been suggested as an indicator of successful response to treatment, whereas a failure to decline or a subsequent rise in IgG titer suggests a possibility of relapse or progression to chronic focal disease [<a href="#rid84">84-86</a>]; however, negative serology does not definitively exclude persistence of active <em>Brucella</em> infection [<a href="#rid82">82,87</a>]. Some patients may have persistent symptoms (which may be attributable to persistent infection or another cause) after completing treatment, even in the setting of declining or negative serology [<a href="#rid88">88,89</a>]. Conversely, elevated levels of IgG antibodies may persist for years in fully treated individuals with no clinical signs of infection [<a href="#rid75">75</a>].</p><p>The above assays (if available) are preferred over the following assays (which are generally not appropriate for monitoring response to treatment):</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-<em>Brucella</em> cytoplasmic or periplasmic protein antibodies (detected by ELISA) — These antibodies are elevated only in active brucellosis [<a href="#rid77">77,90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Molecular techniques — Molecular techniques are inappropriate to establish the success of treatment or to predict relapse. <em>Brucella</em> DNA can be detected using real-time polymerase chain reaction (PCR) techniques in the majority of treated patients throughout the follow-up period, despite apparent clinical recovery. In a significant number of patients, <em>Brucella</em> DNA can remain detectable for months or years after clinical cure and in the absence of any symptoms indicative of chronic disease or relapse [<a href="#rid91">91,92</a>]. Conversely, relapses have been observed in PCR-negative patients [<a href="#rid91">91</a>].</p><p></p><p class="headingAnchor" id="H3657081529"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>Unfavorable outcomes (defined by relapses and therapeutic failures) are usually a result of failure to eradicate intracellular bacteria. Therapeutic failures are usually associated with <em>Brucella</em> spondylitis and have been reported in up to 15 percent of cases [<a href="#rid93">93</a>]. Rarely, moderate to severe sequelae occur in the setting of spondylitis and neurobrucellosis [<a href="#rid45">45,51,62</a>]. </p><p>The prognosis of neurobrucellosis is variable; in one report of 18 patients, complete recovery of neurologic function was observed in 60 percent of cases [<a href="#rid62">62</a>]. With appropriate antimicrobial treatment, the mortality rate of brucellosis is &lt;1 percent [<a href="#rid53">53,93,94</a>]. Endocarditis is the main cause of death attributable to brucellosis [<a href="#rid53">53,95-97</a>].</p><p class="headingAnchor" id="H3837090433"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H1600519573"><span class="h2">General principles</span><span class="headingEndMark"> — </span>Thus far, there are no vaccines for prevention of brucellosis in humans; improved understanding of disease pathogenesis may facilitate identification of vaccine targets [<a href="#rid3">3,4</a>].</p><p>Tools for prevention include treatment of dairy products, precautions for individuals at risk for occupational exposure, precautions to prevent person-to-person transmission, and control of the disease in animals [<a href="#rid95">95</a>] (see  <a class="medical medical_review" href="/d/html/3140.html" rel="external">"Brucellosis: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Transmission'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Raw milk should be boiled or pasteurized; consumption of dairy products made from raw milk should be avoided. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Contact of skin or mucous membranes with infected tissue (such as placenta or miscarriage products) or infected fluids (such as blood, urine, or milk) should be avoided. In addition, inhalation of infected aerosolized particles should be avoided. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In clinical settings:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Standard infection control precautions are warranted. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In the setting of obstetrical procedures for pregnant women with brucellosis, health care personnel should wear standard surgical attire (gown, gloves, face mask, and eye protection). (See  <a class="medical medical_review" href="/d/html/4044.html" rel="external">"Overview of control measures for prevention of surgical site infection in adults"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Manipulation of <em>Brucella </em>cultures should be performed with biosafety level 3 practices and containment equipment  (<a class="graphic graphic_table graphicRef78971" href="/d/graphic/78971.html" rel="external">table 5</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In slaughterhouses, protective measures include separation of the killing floor from other processing areas, using designated spaces for known infected animals, use of protective clothing and disinfectants, and control of air circulation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To reduce the likelihood of person-to-person transmission, patients should be counseled to wait until completion of treatment before unprotected sexual contact; <em>Brucella</em> organisms have been detected in semen and it is unknown how long the risk of sexual transmission persists following initiating of treatment [<a href="#rid98">98</a>]. Lactating women with brucellosis should be counseled to discontinue breastfeeding until completion of treatment. In highly endemic regions, we recommend serologic testing for blood and organ donors.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vaccination of domestic livestock – Available vaccines for prevention of brucellosis in animals include <em>Brucella abortus</em> B19 and RB51 (for cattle) and <em>Brucella melitensis </em>Rev 1 (for small ruminants such as sheep and goats). A sustained vaccination program over several years is required. These are live attenuated vaccines that are also known to cause disease in humans during preparation or by accidental inoculation; inadvertent exposure requires careful follow-up [<a href="#rid3">3,99-103</a>]. (See <a class="local">'Postexposure prophylaxis'</a> below.)</p><p></p><p class="bulletIndent1">There are no suitable vaccines for prevention of <em>B. melitensis</em> in cattle or prevention of <em>Brucella suis</em> in swine [<a href="#rid99">99,104</a>]. </p><p></p><p class="headingAnchor" id="H3984322988"><span class="h2">Screening contacts</span><span class="headingEndMark"> — </span>Screening household members of an index case enables detection of unrecognized cases, facilitating early treatment and prevention of complications [<a href="#rid93">93,95</a>]. Household members of an index case should undergo clinical evaluation for signs and symptoms of brucellosis serologic testing (with repeat testing at 6 and 12 weeks); they should be instructed to seek medical attention if they develop relevant clinical manifestations. Symptomatic individuals should undergo additional diagnostic evaluation as discussed separately. (See  <a class="medical medical_review" href="/d/html/3140.html" rel="external">"Brucellosis: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H3941084145"><span class="h2">Postexposure prophylaxis</span><span class="headingEndMark"> — </span>Microbiology laboratory workers may be at risk for brucellosis after laboratory exposure. We are in agreement with the United States Centers for Disease Control and Prevention's approach to identification of high-risk exposures, recommendations for serologic testing, and postexposures prophylaxis; these are outlined in the table  (<a class="graphic graphic_table graphicRef60500" href="/d/graphic/60500.html" rel="external">table 6</a>) [<a href="#rid105">105,106</a>]. </p><p class="headingAnchor" id="H4166560152"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General treatment principles</strong> – General principles of brucellosis treatment include use of antibiotics with activity in acidic intracellular environments (such as <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> and <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>), use of combination therapy (given high relapse rates with monotherapy), and prolonged duration of treatment. (See <a class="local">'General approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical approach</strong> – For treatment of patients with brucellosis (in the absence of focal disease due to spondylitis, neurobrucellosis, or endocarditis), our approach is as follows  (<a class="graphic graphic_table graphicRef122172" href="/d/graphic/122172.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonpregnant adults</strong> – For nonpregnant adults, we suggest combination therapy with <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> plus an aminoglycoside (<a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a> or <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>) over oral combination therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). The aminoglycoside-based regimen has been associated with lower rates of treatment failure and relapse; oral combination therapy is an acceptable alternative for circumstances in which avoidance of parenteral therapy is preferred. The duration of therapy is six weeks. (See <a class="local">'Nonpregnant adults'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children</strong> – For children, we suggest oral combination therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>), since administration is more convenient than parenteral therapy. Treatment of children ≥8 years consists of <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> plus <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>; for children &lt;8 years, we substitute <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) for doxycycline. The duration of therapy is 6 weeks. (See <a class="local">'Children'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnant patients</strong> – For pregnant patients &lt;36 weeks gestation, we suggest treatment with <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> plus TMP-SMX compared with alternative regimens (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For pregnant patients ≥36 weeks gestation, we administer rifampin monotherapy until delivery (given the risk of neonatal kernicterus with the use of TMP-SMX in the last month of pregnancy). After delivery, we continue combination therapy as in nonpregnant adults and advise that breastfeeding be postponed until after completion of treatment. The total duration of treatment is six weeks. (See <a class="local">'Pregnant women'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of specific complications</strong> – For treatment of focal disease due to spondylitis, neurobrucellosis, or endocarditis, our approach is as follows: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonpregnant adults and children ≥8 years</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Spondylitis</strong> – For nonpregnant adults and children ≥8 years with spondylitis, we suggest treatment with <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> plus <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> plus an aminoglycoside (<a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a> or <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>) compared with alternative regimens  (<a class="graphic graphic_table graphicRef122173" href="/d/graphic/122173.html" rel="external">table 2</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For children &lt;8 years, we substitute TMP-SMX for doxycycline. The total duration of treatment is at least 12 weeks; it is tailored to individual patient circumstances including clinical assessment and follow-up radiographic imaging. (See <a class="local">'Spondylitis'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Neurobrucellosis</strong> – For nonpregnant adults and children ≥8 years with neurobrucellosis, we suggest treatment with <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, and <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> compared with alternative regimens  (<a class="graphic graphic_table graphicRef122174" href="/d/graphic/122174.html" rel="external">table 3</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For children &lt;8 years, we substitute TMP-SMX for doxycycline. The total duration of treatment is at least 12 weeks and may be up to 6 months or longer; it is tailored to individual patient circumstances including clinical assessment, cerebrospinal fluid findings, and follow-up radiographic imaging. (See <a class="local">'Neurobrucellosis'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Endocarditis</strong> – For nonpregnant adults and children ≥8 years with <em>Brucella</em> endocarditis, we suggest treatment with a triple-combination antibiotic regimen including an aminoglycoside (<a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a> or <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>) for the first month, PLUS <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> and <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> compared with alternative regimens both for at least 12 weeks  (<a class="graphic graphic_table graphicRef122175" href="/d/graphic/122175.html" rel="external">table 4</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For children &lt;8 years, we substitute TMP-SMX for doxycycline. The duration of therapy is often extended for 4 to 6 months, tailored to individual patient circumstances including clinical assessment and follow-up echocardiography. In general, most patients with <em>Brucella</em> endocarditis require a combination of antimicrobial therapy and surgery for the best chance of cure; surgical consultation is warranted for all patients with <em>Brucella</em> endocarditis. (See <a class="local">'Endocarditis'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnant patients</strong> – For treatment of pregnant patients with focal disease due to spondylitis, neurobrucellosis, or endocarditis, we suggest treatment with a triple-combination antibiotic regimen including <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, and TMP-SMX compared with alternative regimens (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We avoid use of TMP-SMX during the last month of pregnancy. The duration of therapy is as summarized above. (See <a class="local">'Treatment of specific complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Tools for prevention of brucellosis include avoiding consumption of raw milk, precautions for individuals at risk for occupational exposure, precautions to prevent person-to-person transmission, and control of the disease in animals. Contact of skin or mucous membranes with infected tissue (such as placenta or miscarriage products) or infected fluids should be avoided. Patients should be counseled to wait until completion of treatment before unprotected sexual contact, and lactating women should be advised to discontinue breastfeeding until completion of treatment. (See <a class="local">'Prevention'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Centers for Disease Control (CDC) Brucellosis Reference Guide 2017. https://www.cdc.gov/brucellosis/pdf/brucellosi-reference-guide.pdf (Accessed on May 23, 2019).</li><li><a class="nounderline abstract_t">Ariza J, Bosilkovski M, Cascio A, et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med 2007; 4:e317.</a></li><li class="breakAll">WHO/CDS/EPR/2006.7. Brucellosis in humans and animals Geneva: World Health Organization, 2006.</li><li><a class="nounderline abstract_t">Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med 2005; 352:2325.</a></li><li><a class="nounderline abstract_t">Solera J. Treatment of human brucellosis. J Med Liban 2000; 48:255.</a></li><li><a class="nounderline abstract_t">Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, Sadeghipour P. Antibiotics for treating human brucellosis. Cochrane Database Syst Rev 2012; 10:CD007179.</a></li><li><a class="nounderline abstract_t">Walper SA, Lasarte Aragonés G, Sapsford KE, et al. Detecting Biothreat Agents: From Current Diagnostics to Developing Sensor Technologies. ACS Sens 2018; 3:1894.</a></li><li><a class="nounderline abstract_t">Solera J, Martínez-Alfaro E, Espinosa A. Recognition and optimum treatment of brucellosis. Drugs 1997; 53:245.</a></li><li><a class="nounderline abstract_t">Pappas G, Papadimitriou P, Christou L, Akritidis N. Future trends in human brucellosis treatment. Expert Opin Investig Drugs 2006; 15:1141.</a></li><li><a class="nounderline abstract_t">Al-Tawfiq JA. Therapeutic options for human brucellosis. Expert Rev Anti Infect Ther 2008; 6:109.</a></li><li class="breakAll">Joint Food and Agriculture Organization (FAO), World Health Organization (WHO). FAO-WHO expert committee on brucellosis (Sixth report). WHO technical report series, no 740. Geneva: World Health Organization; 1986: p. 56-7.</li><li><a class="nounderline abstract_t">Solís García del Pozo J, Solera J. Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis. PLoS One 2012; 7:e32090.</a></li><li><a class="nounderline abstract_t">Skalsky K, Yahav D, Bishara J, et al. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. BMJ 2008; 336:701.</a></li><li><a class="nounderline abstract_t">Alavi SM, Alavi L. Treatment of brucellosis: a systematic review of studies in recent twenty years. Caspian J Intern Med 2013; 4:636.</a></li><li><a class="nounderline abstract_t">Ariza J, Gudiol F, Pallares R, et al. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, double-blind study. Ann Intern Med 1992; 117:25.</a></li><li><a class="nounderline abstract_t">Hasanjani Roushan MR, Mohraz M, Hajiahmadi M, et al. Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans. Clin Infect Dis 2006; 42:1075.</a></li><li><a class="nounderline abstract_t">Huang S, Wang H, Li F, et al. Better efficacy of triple antibiotics therapy for human brucellosis: A systematic review and meta-analysis. PLoS Negl Trop Dis 2023; 17:e0011590.</a></li><li><a class="nounderline abstract_t">Mantur BG, Akki AS, Mangalgi SS, et al. Childhood brucellosis--a microbiological, epidemiological and clinical study. J Trop Pediatr 2004; 50:153.</a></li><li><a class="nounderline abstract_t">Ranjbar M, Keramat F, Mamani M, et al. Comparison between doxycycline-rifampin-amikacin and doxycycline-rifampin regimens in the treatment of brucellosis. Int J Infect Dis 2007; 11:152.</a></li><li><a class="nounderline abstract_t">Mile B, Valerija K, Krsto G, et al. Doxycycline-rifampin versus doxycycline-rifampin-gentamicin in treatment of human brucellosis. Trop Doct 2012; 42:13.</a></li><li><a class="nounderline abstract_t">Vrioni G, Bourdakis A, Pappas G, et al. Administration of a triple versus a standard double antimicrobial regimen for human brucellosis more efficiently eliminates bacterial DNA load. Antimicrob Agents Chemother 2014; 58:7541.</a></li><li><a class="nounderline abstract_t">Hasanain A, Mahdy R, Mohamed A, Ali M. A randomized, comparative study of dual therapy (doxycycline-rifampin) versus triple therapy (doxycycline-rifampin-levofloxacin) for treating acute/subacute brucellosis. Braz J Infect Dis 2016; 20:250.</a></li><li><a class="nounderline abstract_t">Bosilkovski M, Keramat F, Arapović J. The current therapeutical strategies in human brucellosis. Infection 2021; 49:823.</a></li><li><a class="nounderline abstract_t">Falagas ME, Bliziotis IA. Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies. Antimicrob Agents Chemother 2006; 50:22.</a></li><li><a class="nounderline abstract_t">Akova M, Uzun O, Akalin HE, et al. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother 1993; 37:1831.</a></li><li><a class="nounderline abstract_t">Karabay O, Sencan I, Kayas D, Sahin I. Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial [ISRCTN11871179]. BMC Infect Dis 2004; 4:18.</a></li><li><a class="nounderline abstract_t">Ersoy Y, Sonmez E, Tevfik MR, But AD. Comparison of three different combination therapies in the treatment of human brucellosis. Trop Doct 2005; 35:210.</a></li><li><a class="nounderline abstract_t">Issa H, Jamal M. Brucellosis in children in south Jordan. East Mediterr Health J 1999; 5:895.</a></li><li><a class="nounderline abstract_t">Bosilkovski M, Krteva L, Caparoska S, et al. Childhood brucellosis: Review of 317 cases. Asian Pac J Trop Med 2015; 8:1027.</a></li><li><a class="nounderline abstract_t">Khuri-Bulos NA, Daoud AH, Azab SM. Treatment of childhood brucellosis: results of a prospective trial on 113 children. Pediatr Infect Dis J 1993; 12:377.</a></li><li><a class="nounderline abstract_t">Lubani MM, Dudin KI, Sharda DC, et al. A multicenter therapeutic study of 1100 children with brucellosis. Pediatr Infect Dis J 1989; 8:75.</a></li><li><a class="nounderline abstract_t">al-Eissa YA, Kambal AM, al-Nasser MN, et al. Childhood brucellosis: a study of 102 cases. Pediatr Infect Dis J 1990; 9:74.</a></li><li><a class="nounderline abstract_t">Tanir G, Tufekci SB, Tuygun N. Presentation, complications, and treatment outcome of brucellosis in Turkish children. Pediatr Int 2009; 51:114.</a></li><li><a class="nounderline abstract_t">El-Amin EO, George L, Kutty NK, et al. Brucellosis in children of Dhofar Region, Oman. Saudi Med J 2001; 22:610.</a></li><li><a class="nounderline abstract_t">Roushan MR, Mohraz M, Janmohammadi N, Hajiahmadi M. Efficacy of cotrimoxazole and rifampin for 6 or 8 weeks of therapy in childhood brucellosis. Pediatr Infect Dis J 2006; 25:544.</a></li><li><a class="nounderline abstract_t">Gottesman G, Vanunu D, Maayan MC, et al. Childhood brucellosis in Israel. Pediatr Infect Dis J 1996; 15:610.</a></li><li><a class="nounderline abstract_t">Sánchez-Tamayo T, Colmenero JD, Martínez-Cortés F, et al. Failure of short-term antimicrobial therapy in childhood brucellosis. Pediatr Infect Dis J 1997; 16:323.</a></li><li><a class="nounderline abstract_t">Vilchez G, Espinoza M, D'Onadio G, et al. Brucellosis in pregnancy: clinical aspects and obstetric outcomes. Int J Infect Dis 2015; 38:95.</a></li><li><a class="nounderline abstract_t">Khan MY, Mah MW, Memish ZA. Brucellosis in pregnant women. Clin Infect Dis 2001; 32:1172.</a></li><li><a class="nounderline abstract_t">Gulsun S, Aslan S, Satici O, Gul T. Brucellosis in pregnancy. Trop Doct 2011; 41:82.</a></li><li><a class="nounderline abstract_t">Bosilkovski M, Arapović J, Keramat F. Human brucellosis in pregnancy - an overview. Bosn J Basic Med Sci 2020; 20:415.</a></li><li><a class="nounderline abstract_t">Roushan MR, Baiani M, Asnafi N, Saedi F. Outcomes of 19 pregnant women with brucellosis in Babol, northern Iran. Trans R Soc Trop Med Hyg 2011; 105:540.</a></li><li><a class="nounderline abstract_t">Ford N, Shubber Z, Jao J, et al. Safety of cotrimoxazole in pregnancy: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2014; 66:512.</a></li><li><a class="nounderline abstract_t">Inan A, Erdem H, Elaldi N, et al. Brucellosis in pregnancy: results of multicenter ID-IRI study. Eur J Clin Microbiol Infect Dis 2019; 38:1261.</a></li><li><a class="nounderline abstract_t">Colmenero JD, Ruiz-Mesa JD, Plata A, et al. Clinical findings, therapeutic approach, and outcome of brucellar vertebral osteomyelitis. Clin Infect Dis 2008; 46:426.</a></li><li><a class="nounderline abstract_t">Alp E, Doganay M. Current therapeutic strategy in spinal brucellosis. Int J Infect Dis 2008; 12:573.</a></li><li><a class="nounderline abstract_t">Alp E, Koc RK, Durak AC, et al. Doxycycline plus streptomycin versus ciprofloxacin plus rifampicin in spinal brucellosis [ISRCTN31053647]. BMC Infect Dis 2006; 6:72.</a></li><li><a class="nounderline abstract_t">Pappas G, Seitaridis S, Akritidis N, Tsianos E. Treatment of brucella spondylitis: lessons from an impossible meta-analysis and initial report of efficacy of a fluoroquinolone-containing regimen. Int J Antimicrob Agents 2004; 24:502.</a></li><li><a class="nounderline abstract_t">Ulu-Kilic A, Karakas A, Erdem H, et al. Update on treatment options for spinal brucellosis. Clin Microbiol Infect 2014; 20:O75.</a></li><li><a class="nounderline abstract_t">Ioannou S, Karadima D, Pneumaticos S, et al. Efficacy of prolonged antimicrobial chemotherapy for brucellar spondylodiscitis. Clin Microbiol Infect 2011; 17:756.</a></li><li><a class="nounderline abstract_t">Solera J, Lozano E, Martínez-Alfaro E, et al. Brucellar spondylitis: review of 35 cases and literature survey. Clin Infect Dis 1999; 29:1440.</a></li><li><a class="nounderline abstract_t">Smailnejad Gangi SM, Hasanjani Roushan MR, Janmohammadi N, et al. Outcomes of treatment in 50 cases with spinal brucellosis in Babol, Northern Iran. J Infect Dev Ctries 2012; 6:654.</a></li><li><a class="nounderline abstract_t">Colmenero JD, Reguera JM, Martos F, et al. Complications associated with Brucella melitensis infection: a study of 530 cases. Medicine (Baltimore) 1996; 75:195.</a></li><li><a class="nounderline abstract_t">Zhao S, Cheng Y, Liao Y, et al. Treatment Efficacy and Risk Factors of Neurobrucellosis. Med Sci Monit 2016; 22:1005.</a></li><li><a class="nounderline abstract_t">Pappas G, Akritidis N, Christou L. Treatment of neurobrucellosis: what is known and what remains to be answered. Expert Rev Anti Infect Ther 2007; 5:983.</a></li><li><a class="nounderline abstract_t">Gul HC, Erdem H, Gorenek L, et al. Management of neurobrucellosis: an assessment of 11 cases. Intern Med 2008; 47:995.</a></li><li><a class="nounderline abstract_t">Erdem H, Ulu-Kilic A, Kilic S, et al. Efficacy and tolerability of antibiotic combinations in neurobrucellosis: results of the Istanbul study. Antimicrob Agents Chemother 2012; 56:1523.</a></li><li><a class="nounderline abstract_t">Habeeb YK, Al-Najdi AK, Sadek SA, Al-Onaizi E. Paediatric neurobrucellosis: case report and literature review. J Infect 1998; 37:59.</a></li><li><a class="nounderline abstract_t">Omar FZ, Zuberi S, Minns RA. Neurobrucellosis in childhood: six new cases and a review of the literature. Dev Med Child Neurol 1997; 39:762.</a></li><li><a class="nounderline abstract_t">Lubani MM, Dudin KI, Araj GF, et al. Neurobrucellosis in children. Pediatr Infect Dis J 1989; 8:79.</a></li><li><a class="nounderline abstract_t">Yetkin MA, Bulut C, Erdinc FS, et al. Evaluation of the clinical presentations in neurobrucellosis. Int J Infect Dis 2006; 10:446.</a></li><li><a class="nounderline abstract_t">McLean DR, Russell N, Khan MY. Neurobrucellosis: clinical and therapeutic features. Clin Infect Dis 1992; 15:582.</a></li><li><a class="nounderline abstract_t">Lulu AR, Araj GF, Khateeb MI, et al. Human brucellosis in Kuwait: a prospective study of 400 cases. Q J Med 1988; 66:39.</a></li><li><a class="nounderline abstract_t">Cay S, Cagirci G, Maden O, et al. Brucella endocarditis - a registry study. Kardiol Pol 2009; 67:274.</a></li><li><a class="nounderline abstract_t">Cohen N, Golik A, Alon I, et al. Conservative treatment for Brucella endocarditis. Clin Cardiol 1997; 20:291.</a></li><li><a class="nounderline abstract_t">Keshtkar-Jahromi M, Razavi SM, Gholamin S, et al. Medical versus medical and surgical treatment for brucella endocarditis. Ann Thorac Surg 2012; 94:2141.</a></li><li><a class="nounderline abstract_t">Mert A, Kocak F, Ozaras R, et al. The role of antibiotic treatment alone for the management of Brucella endocarditis in adults: a case report and literature review. Ann Thorac Cardiovasc Surg 2002; 8:381.</a></li><li><a class="nounderline abstract_t">Reguera JM, Alarcón A, Miralles F, et al. Brucella endocarditis: clinical, diagnostic, and therapeutic approach. Eur J Clin Microbiol Infect Dis 2003; 22:647.</a></li><li><a class="nounderline abstract_t">Koruk ST, Erdem H, Koruk I, et al. Management of Brucella endocarditis: results of the Gulhane study. Int J Antimicrob Agents 2012; 40:145.</a></li><li><a class="nounderline abstract_t">Ariza J, Corredoira J, Pallares R, et al. Characteristics of and risk factors for relapse of brucellosis in humans. Clin Infect Dis 1995; 20:1241.</a></li><li><a class="nounderline abstract_t">Roushan MR, Gangi SM, Ahmadi SA. Comparison of the efficacy of two months of treatment with co-trimoxazole plus doxycycline vs. co-trimoxazole plus rifampin in brucellosis. Swiss Med Wkly 2004; 134:564.</a></li><li><a class="nounderline abstract_t">Ben-Shimol S, Farahvar S, Fruchtman Y, Justman N. Factors Associated With Single and Recurrent Bacteremia in Childhood Brucellosis. J Pediatric Infect Dis Soc 2020; 9:664.</a></li><li><a class="nounderline abstract_t">Bosilkovski M, Krteva L, Caparoska S, Dimzova M. Osteoarticular involvement in brucellosis: study of 196 cases in the Republic of Macedonia. Croat Med J 2004; 45:727.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Third Case of Rifampin/Penicillin-Resistant Strain of RB51 Brucella from Consuming Raw Milk. https://emergency.cdc.gov/han/han00417.asp (Accessed on January 25, 2019).</li><li><a class="nounderline abstract_t">Gazapo E, Gonzalez Lahoz J, Subiza JL, et al. Changes in IgM and IgG antibody concentrations in brucellosis over time: importance for diagnosis and follow-up. J Infect Dis 1989; 159:219.</a></li><li><a class="nounderline abstract_t">Pellicer T, Ariza J, Foz A, et al. Specific antibodies detected during relapse of human brucellosis. J Infect Dis 1988; 157:918.</a></li><li><a class="nounderline abstract_t">Baldi PC, Miguel SE, Fossati CA, Wallach JC. Serological follow-up of human brucellosis by measuring IgG antibodies to lipopolysaccharide and cytoplasmic proteins of Brucella species. Clin Infect Dis 1996; 22:446.</a></li><li><a class="nounderline abstract_t">Ariza J, Pellicer T, Pallarés R, et al. Specific antibody profile in human brucellosis. Clin Infect Dis 1992; 14:131.</a></li><li><a class="nounderline abstract_t">Roushan MR, Amiri MJ, Laly A, et al. Follow-up standard agglutination and 2-mercaptoethanol tests in 175 clinically cured cases of human brucellosis. Int J Infect Dis 2010; 14:e250.</a></li><li><a class="nounderline abstract_t">Araj GF. Update on laboratory diagnosis of human brucellosis. Int J Antimicrob Agents 2010; 36 Suppl 1:S12.</a></li><li><a class="nounderline abstract_t">Bosilkovski M, Katerina S, Zaklina S, Ivan V. The role of Brucellacapt test for follow-up patients with brucellosis. Comp Immunol Microbiol Infect Dis 2010; 33:435.</a></li><li><a class="nounderline abstract_t">Al Dahouk S, Tomaso H, Nöckler K, et al. Laboratory-based diagnosis of brucellosis--a review of the literature. Part II: serological tests for brucellosis. Clin Lab 2003; 49:577.</a></li><li><a class="nounderline abstract_t">Mantur BG, Biradar MS, Bidri RC, et al. Protean clinical manifestations and diagnostic challenges of human brucellosis in adults: 16 years' experience in an endemic area. J Med Microbiol 2006; 55:897.</a></li><li><a class="nounderline abstract_t">Avijgan M, Rostamnezhad M, Jahanbani-Ardakani H. Clinical and serological approach to patients with brucellosis: A common diagnostic dilemma and a worldwide perspective. Microb Pathog 2019; 129:125.</a></li><li><a class="nounderline abstract_t">Edathodu J, Alamri M, Alshangiti KA, et al. Clinical manifestations and treatment outcomes of human brucellosis at a tertiary care center in Saudi Arabia. Ann Saudi Med 2021; 41:109.</a></li><li><a class="nounderline abstract_t">Alsubaie SA, Turkistani SA, Zeaiter AA, Thabit AK. Lack of correlation of Brucella antibody titers with clinical outcomes and culture positivity of brucellosis. Trop Dis Travel Med Vaccines 2021; 7:5.</a></li><li><a class="nounderline abstract_t">Payne DJ. Letter: Chronic brucellosis. Br Med J 1974; 2:221.</a></li><li><a class="nounderline abstract_t">Young EJ. Serologic diagnosis of human brucellosis: analysis of 214 cases by agglutination tests and review of the literature. Rev Infect Dis 1991; 13:359.</a></li><li><a class="nounderline abstract_t">Morata P, Queipo-Ortuño MI, Reguera JM, et al. Posttreatment follow-Up of brucellosis by PCR assay. J Clin Microbiol 1999; 37:4163.</a></li><li><a class="nounderline abstract_t">Goldbaum FA, Rubbi CP, Wallach JC, et al. Differentiation between active and inactive human brucellosis by measuring antiprotein humoral immune responses. J Clin Microbiol 1992; 30:604.</a></li><li><a class="nounderline abstract_t">Navarro E, Segura JC, Castaño MJ, Solera J. Use of real-time quantitative polymerase chain reaction to monitor the evolution of Brucella melitensis DNA load during therapy and post-therapy follow-up in patients with brucellosis. Clin Infect Dis 2006; 42:1266.</a></li><li><a class="nounderline abstract_t">Vrioni G, Pappas G, Priavali E, et al. An eternal microbe: Brucella DNA load persists for years after clinical cure. Clin Infect Dis 2008; 46:e131.</a></li><li><a class="nounderline abstract_t">Bosilkovski M, Krteva L, Dimzova M, et al. Human brucellosis in Macedonia - 10 years of clinical experience in endemic region. Croat Med J 2010; 51:327.</a></li><li><a class="nounderline abstract_t">Aygen B, Doganay M, Sumerkan B, et al. Clinical manifestations, complications and treatment of brucellosis: a retrospective evaluation of 480 patients. Med Malad Infect 2002; 32:485.</a></li><li><a class="nounderline abstract_t">Mantur BG, Amarnath SK, Shinde RS. Review of clinical and laboratory features of human brucellosis. Indian J Med Microbiol 2007; 25:188.</a></li><li class="breakAll">Gotuzzo E, Pappas G. Brucellosis. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd ed, Guerrant RL, Walker DH, Weller PF (Eds), Saunders Elsevier, Philadelphia 2011. p.271.</li><li><a class="nounderline abstract_t">Doganay M, Aygen B. Human brucellosis: An overview. Int J Infect Dis 2003; 7:173.</a></li><li><a class="nounderline abstract_t">Tuon FF, Gondolfo RB, Cerchiari N. Human-to-human transmission of Brucella - a systematic review. Trop Med Int Health 2017; 22:539.</a></li><li><a class="nounderline abstract_t">Young EJ. Brucellosis: current epidemiology, diagnosis, and management. Curr Clin Top Infect Dis 1995; 15:115.</a></li><li><a class="nounderline abstract_t">Godfroid J, Cloeckaert A, Liautard JP, et al. From the discovery of the Malta fever's agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis. Vet Res 2005; 36:313.</a></li><li><a class="nounderline abstract_t">Cossaboom CM, Kharod GA, Salzer JS, et al. Notes from the Field: Brucella abortus Vaccine Strain RB51 Infection and Exposures Associated with Raw Milk Consumption - Wise County, Texas, 2017. MMWR Morb Mortal Wkly Rep 2018; 67:286.</a></li><li><a class="nounderline abstract_t">Hatcher SM, Shih D, Holderman J, et al. Notes from the Field: Adverse Event Associated with Unintentional Exposure to the Brucella abortus RB51 Vaccine - Oregon, December 2017. MMWR Morb Mortal Wkly Rep 2018; 67:747.</a></li><li class="breakAll">Wright SG. Brucellosis. In: Hunter’s Tropical Medicine and Emerging Infectious Diseases, 8th ed, Strickland GT (Ed), W.B. Saunders Company, Philadelphia 2000. p.416.</li><li class="breakAll">Bosilkovski M. Brucellosis: It is not only Malta!. In: Zoonoses-Infections Affecting Humans and Animals: Focus on Public Health Aspects, Sing A (Ed), Springer, 2014. p.287.</li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Laboratory-acquired brucellosis--Indiana and Minnesota, 2006. MMWR Morb Mortal Wkly Rep 2008; 57:39.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Exposure to RB51 through Raw Milk or Milk Products: How to Reduce Risk of Infection. https://www.cdc.gov/brucellosis/clinicians/rb51-raw-milk.html (Accessed on July 01, 2019).</li></ol></div><div id="topicVersionRevision">Topic 121314 Version 12.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.cdc.gov/brucellosis/pdf/brucellosi-reference-guide.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Centers for Disease Control (CDC) Brucellosis Reference Guide 2017. https://www.cdc.gov/brucellosis/pdf/brucellosi-reference-guide.pdf (Accessed on May 23, 2019).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18162038" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18162038" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930423" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11214198" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Treatment of human brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23076931" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antibiotics for treating human brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30080029" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Detecting Biothreat Agents: From Current Diagnostics to Developing Sensor Technologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9028744" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Recognition and optimum treatment of brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16989591" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Future trends in human brucellosis treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18251668" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Therapeutic options for human brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18251668" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Therapeutic options for human brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22393379" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18321957" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24009951" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment of brucellosis: a systematic review of studies in recent twenty years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1596044" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16575723" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37708094" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Better efficacy of triple antibiotics therapy for human brucellosis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15233191" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Childhood brucellosis--a microbiological, epidemiological and clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16798042" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparison between doxycycline-rifampin-amikacin and doxycycline-rifampin regimens in the treatment of brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22290107" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Doxycycline-rifampin versus doxycycline-rifampin-gentamicin in treatment of human brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25246401" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Administration of a triple versus a standard double antimicrobial regimen for human brucellosis more efficiently eliminates bacterial DNA load.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27086734" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A randomized, comparative study of dual therapy (doxycycline-rifampin) versus triple therapy (doxycycline-rifampin-levofloxacin) for treating acute/subacute brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33650077" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The current therapeutical strategies in human brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16377662" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8239591" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15214959" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial [ISRCTN11871179].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16354469" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparison of three different combination therapies in the treatment of human brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10983528" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Brucellosis in children in south Jordan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26706674" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Childhood brucellosis: Review of 317 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8327297" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Treatment of childhood brucellosis: results of a prospective trial on 113 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2649867" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A multicenter therapeutic study of 1100 children with brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2314956" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Childhood brucellosis: a study of 102 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19371290" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Presentation, complications, and treatment outcome of brucellosis in Turkish children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11479644" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Brucellosis in children of Dhofar Region, Oman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16732154" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Efficacy of cotrimoxazole and rifampin for 6 or 8 weeks of therapy in childhood brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8823856" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Childhood brucellosis in Israel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9076822" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Failure of short-term antimicrobial therapy in childhood brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26159844" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Brucellosis in pregnancy: clinical aspects and obstetric outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11283806" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Brucellosis in pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21378061" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Brucellosis in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31782698" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Human brucellosis in pregnancy - an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21742362" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Outcomes of 19 pregnant women with brucellosis in Babol, northern Iran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24853309" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Safety of cotrimoxazole in pregnancy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30989418" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Brucellosis in pregnancy: results of multicenter ID-IRI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18181740" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinical findings, therapeutic approach, and outcome of brucellar vertebral osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18539496" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Current therapeutic strategy in spinal brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16606473" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Doxycycline plus streptomycin versus ciprofloxacin plus rifampicin in spinal brucellosis [ISRCTN31053647].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15519485" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment of brucella spondylitis: lessons from an impossible meta-analysis and initial report of efficacy of a fluoroquinolone-containing regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24118178" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Update on treatment options for spinal brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20518794" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Efficacy of prolonged antimicrobial chemotherapy for brucellar spondylodiscitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585793" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Brucellar spondylitis: review of 35 cases and literature survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23000864" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Outcomes of treatment in 50 cases with spinal brucellosis in Babol, Northern Iran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8699960" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Complications associated with Brucella melitensis infection: a study of 530 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27018084" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment Efficacy and Risk Factors of Neurobrucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18039082" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Treatment of neurobrucellosis: what is known and what remains to be answered.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18520109" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Management of neurobrucellosis: an assessment of 11 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22155822" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Efficacy and tolerability of antibiotic combinations in neurobrucellosis: results of the Istanbul study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9733381" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Paediatric neurobrucellosis: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9393891" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Neurobrucellosis in childhood: six new cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2704607" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Neurobrucellosis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16914346" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Evaluation of the clinical presentations in neurobrucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1420670" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Neurobrucellosis: clinical and therapeutic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3051080" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Human brucellosis in Kuwait: a prospective study of 400 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19378233" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Brucella endocarditis - a registry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9068918" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Conservative treatment for Brucella endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23102495" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Medical versus medical and surgical treatment for brucella endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12517300" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The role of antibiotic treatment alone for the management of Brucella endocarditis in adults: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14566576" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Brucella endocarditis: clinical, diagnostic, and therapeutic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22727531" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Management of Brucella endocarditis: results of the Gulhane study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7620005" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Characteristics of and risk factors for relapse of brucellosis in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15551160" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Comparison of the efficacy of two months of treatment with co-trimoxazole plus doxycycline vs. co-trimoxazole plus rifampin in brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31840752" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Factors Associated With Single and Recurrent Bacteremia in Childhood Brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15578807" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Osteoarticular involvement in brucellosis: study of 196 cases in the Republic of Macedonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15578807" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Osteoarticular involvement in brucellosis: study of 196 cases in the Republic of Macedonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2915152" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Changes in IgM and IgG antibody concentrations in brucellosis over time: importance for diagnosis and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3361155" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Specific antibodies detected during relapse of human brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8852961" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Serological follow-up of human brucellosis by measuring IgG antibodies to lipopolysaccharide and cytoplasmic proteins of Brucella species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1571417" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Specific antibody profile in human brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19648045" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Follow-up standard agglutination and 2-mercaptoethanol tests in 175 clinically cured cases of human brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20692128" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Update on laboratory diagnosis of human brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19625085" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The role of Brucellacapt test for follow-up patients with brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14651329" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Laboratory-based diagnosis of brucellosis--a review of the literature. Part II: serological tests for brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16772417" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Protean clinical manifestations and diagnostic challenges of human brucellosis in adults: 16 years' experience in an endemic area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30742950" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Clinical and serological approach to patients with brucellosis: A common diagnostic dilemma and a worldwide perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33818142" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Clinical manifestations and treatment outcomes of human brucellosis at a tertiary care center in Saudi Arabia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33531081" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Lack of correlation of Brucella antibody titers with clinical outcomes and culture positivity of brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4208904" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Letter: Chronic brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1866536" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Serologic diagnosis of human brucellosis: analysis of 214 cases by agglutination tests and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10565954" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Posttreatment follow-Up of brucellosis by PCR assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1551977" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Differentiation between active and inactive human brucellosis by measuring antiprotein humoral immune responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16586386" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Use of real-time quantitative polymerase chain reaction to monitor the evolution of Brucella melitensis DNA load during therapy and post-therapy follow-up in patients with brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18462106" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : An eternal microbe: Brucella DNA load persists for years after clinical cure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20718086" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Human brucellosis in Macedonia - 10 years of clinical experience in endemic region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Clinical manifestations, complications and treatment of brucellosis: a retrospective evaluation of 480 patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17901634" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Review of clinical and laboratory features of human brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17901634" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Review of clinical and laboratory features of human brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Human brucellosis: An overview</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28196298" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Human-to-human transmission of Brucella - a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7546364" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Brucellosis: current epidemiology, diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15845228" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : From the discovery of the Malta fever's agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29518066" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Notes from the Field: Brucella abortus Vaccine Strain RB51 Infection and Exposures Associated with Raw Milk Consumption - Wise County, Texas, 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29975674" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Notes from the Field: Adverse Event Associated with Unintentional Exposure to the Brucella abortus RB51 Vaccine - Oregon, December 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29975674" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Notes from the Field: Adverse Event Associated with Unintentional Exposure to the Brucella abortus RB51 Vaccine - Oregon, December 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29975674" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Notes from the Field: Adverse Event Associated with Unintentional Exposure to the Brucella abortus RB51 Vaccine - Oregon, December 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18199967" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Laboratory-acquired brucellosis--Indiana and Minnesota, 2006.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
